Drug Attitude Inventory (DAI-30) in a Spanish population;El Cuestionario de Actitud hacia la Medicación (Drug Ittitude Inventory: DAI-30) en población Española

Archivos de Psiquiatria

Volumn 64, Issue 3, 2001, Pages 261-271

  Cabeza, I G ^a   Beldarrain J A H ^a   Lopez C A ^a   Amador, M S ^a   Gonzales de Chavez M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antipsychotics; Drug Attitude Inventory; Subjetive response

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DISEASE COURSE; FACTORIAL ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MENTAL PATIENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA; SPAIN;

EID: 0034804963     PISSN: 15760367     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. On the mechanism of action of neuroleptic drugs: A theoretical psycho-dynamic explanation
2. Individual differences in response to pharmacotherapy
3. Non-specific factors in the drug therapy of schizophrenic patients
4. Subjective response to neuroleptics in schizophrenia
5. Subjective response as a predictor of outcome in pharmacotherapy
6. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity
7. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures
8. La perception subjective de l'effet des neuroleptiques chez des patients schizophrènes ambulatoires: Une étude transversale
9. Rating of medication influences (ROMI) scale in schizophrenia
10. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables
11. Patients' subjective experiencies on antipsychotic medications: Implications for outcome and quality of life
12. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes
13. The UKU side effect rating scale
14. The global assesment scale
15. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors
16. Early treatment events and prediction of response to neuroleptics in schizophrenia
17. Quality of life in schizophrenia: Insight and subjective response to neuroleptics